{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:46:44Z","timestamp":1785577604922,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"},{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the light of increasing evidence that benign prostatic hyperplasia is associated with cardiovascular disease, we have investigated the relationship between prostatic blood flow and prostatic hyperplasia in the spontaneously-hypertensive-rat (SHR). Twelve-week-old male SHRs were treated with nicorandil for six weeks. Wistar-Kyoto rats were used as controls. Six weeks after nicorandil treatment, blood pressure and the prostatic blood flow were estimated and tissue levels of malondialdehyde, HIF-1\u03b1, TGF-\u03b21, bFGF, dihydrotestosterone and \u03b1-SMA were measured. SHRs showed significant increases in blood pressure, tissue levels of malondialdehyde, HIF-1\u03b1, TGF-\u03b21, bFGF, \u03b1-SMA and a significant decrease in the prostatic blood flow. Although treatment with nicorandil failed to alter the blood-pressure and \u03b1-SMA, it significantly ameliorated the increased levels of malondialdehyde, HIF-1\u03b1, TGF-\u03b21 and bFGF. There were no significant differences in tissue levels of dihydrotestosterone among any groups. These data indicate that development of prostatic hyperplasia may be associated with prostatic hypoxia, which nicorandil prevents via its effect to increase the blood flow.<\/jats:p>","DOI":"10.1038\/srep03822","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T10:01:09Z","timestamp":1390384869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH"],"prefix":"10.1038","volume":"4","author":[{"given":"Motoaki","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Tsounapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Sejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"key":"BFsrep03822_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJMcp1106637","volume":"367","author":"AV Sarma","year":"2012","unstructured":"Sarma, A. V. & Wei, J. T. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 367, 248\u2013257 (2012).","journal-title":"N Engl J Med"},{"key":"BFsrep03822_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.exger.2004.12.008","volume":"40","author":"G Untergasser","year":"2005","unstructured":"Untergasser, G., Madersbacher, S. & Berger, P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 40, 121\u2013128 (2005).","journal-title":"Exp Gerontol"},{"key":"BFsrep03822_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0090-4295(98)00536-6","volume":"53","author":"AM De Marzo","year":"1999","unstructured":"De Marzo, A. M., Coffey, D. S. & Nelson, W. G. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 53, 29\u201339; discussion 39\u201342 (1999).","journal-title":"Urology"},{"key":"BFsrep03822_CR4","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S0022-5347(05)68340-1","volume":"162","author":"MS Steiner","year":"1999","unstructured":"Steiner, M. S., Couch, R. C., Raghow, S. & Stauffer, D. The chimpanzee as a model of human benign prostatic hyperplasia. J Urol 162, 1454\u20131461 (1999).","journal-title":"J Urol"},{"key":"BFsrep03822_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1293\/tox.4.183","volume":"4","author":"H Nakamura","year":"1991","unstructured":"Nakamura, H. et al. Morphological abnormality of the epithelium in the prostate gland of spontaneously hypertensive rats. J Toxicol Pathol 4, 183\u2013193 (1991).","journal-title":"J Toxicol Pathol"},{"key":"BFsrep03822_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2131\/jts.19.4_213","volume":"19","author":"S Furukawa","year":"1994","unstructured":"Furukawa, S. et al. Influence of efonidipine hydrochloride, calcium antagonist on the epithelium of prostates in spontaneously hypertensive rats. J Toxicol Sci 19, 213\u2013217 (1994).","journal-title":"J Toxicol Sci"},{"key":"BFsrep03822_CR7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.1939-4640.2000.tb03276.x","volume":"21","author":"E Golomb","year":"2000","unstructured":"Golomb, E., Rosenzweig, N., Eilam, R. & Abramovici, A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 21, 58\u201364 (2000).","journal-title":"J Androl"},{"key":"BFsrep03822_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0090-4295(02)02167-2","volume":"61","author":"M Yamashita","year":"2003","unstructured":"Yamashita, M., Zhang, X., Shiraishi, T., Uetsuki, H. & Kakehi, Y. Determination of percent area density of epithelial and stromal components in development of prostatic hyperplasia in spontaneously hypertensive rats. Urology 61, 484\u2013489 (2003).","journal-title":"Urology"},{"key":"BFsrep03822_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.lfs.2007.05.004","volume":"81","author":"M Yono","year":"2007","unstructured":"Yono, M., Yamamoto, Y., Yoshida, M., Ueda, S. & Latifpour, J. Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract. Life Sci 81, 218\u2013222 (2007).","journal-title":"Life Sci"},{"key":"BFsrep03822_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1293\/tox.5.101","volume":"5","author":"H Nakamura","year":"1992","unstructured":"Nakamura, H. & Itakura, C. Influence of terazosin on the epithelium in the prostate gland of spontaneously hypertensive rats. J Toxicoi Pathol 5, 101\u2013104 (1992).","journal-title":"J Toxicoi Pathol"},{"key":"BFsrep03822_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.abb.2003.06.002","volume":"420","author":"C Ceconi","year":"2003","unstructured":"Ceconi, C., Boraso, A., Cargnoni, A. & Ferrari, R. Oxidative stress in cardiovascular disease: myth or fact? Arch Biochem Biophys 420, 217\u2013221 (2003).","journal-title":"Arch Biochem Biophys"},{"key":"BFsrep03822_CR12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0891-5849(00)00226-4","volume":"28","author":"K Uchida","year":"2000","unstructured":"Uchida, K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28, 1685\u20131696 (2000).","journal-title":"Free Radic Biol Med"},{"key":"BFsrep03822_CR13","doi-asserted-by":"publisher","first-page":"18J","DOI":"10.1016\/0002-9149(89)90200-2","volume":"63","author":"N Taira","year":"1989","unstructured":"Taira, N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63, 18J\u201324J (1989).","journal-title":"Am J Cardiol"},{"key":"BFsrep03822_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2165\/00003495-200060040-00007","volume":"60","author":"A Markham","year":"2000","unstructured":"Markham, A., Plosker, G. L. & Goa, K. L. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 60, 955\u2013974 (2000).","journal-title":"Drugs"},{"key":"BFsrep03822_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/nau.21213","volume":"31","author":"M Saito","year":"2012","unstructured":"Saito, M. et al. Nicorandil ameliorates hypertension-related bladder dysfunction in the rat. Neurourol Urodyn 31, 695\u2013701 (2012).","journal-title":"Neurourol Urodyn"},{"key":"BFsrep03822_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1046\/j.1464-410x.2001.00103.x","volume":"87","author":"Y Niu","year":"2001","unstructured":"Niu, Y., Xu, Y., Zhang, J., Bai, J., Yang, H. & Ma, T. Proliferation and differentiation of prostatic stromal cells. BJU Int 87, 386\u2013393 (2001).","journal-title":"BJU Int"},{"key":"BFsrep03822_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11934-002-0051-2","volume":"3","author":"MA Ghafar","year":"2002","unstructured":"Ghafar, M. A., Puchner, P. J., Anastasiadis, A. G., Cabelin, M. A. & Buttyan, R. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 3, 292\u2013296 (2002).","journal-title":"Curr Urol Rep"},{"key":"BFsrep03822_CR18","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/j.1464-410X.2006.06400.x","volume":"98","author":"AP Berger","year":"2006","unstructured":"Berger, A. P. et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 98, 1038\u20131042 (2006).","journal-title":"BJU Int"},{"key":"BFsrep03822_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1464-410X.2006.06306.x","volume":"98","author":"AP Berger","year":"2006","unstructured":"Berger, A. P. et al. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int 98, 587\u2013590 (2006).","journal-title":"BJU Int"},{"key":"BFsrep03822_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/ars.2007.1914","volume":"10","author":"K Koli","year":"2008","unstructured":"Koli, K., Myllarniemi, M., Keski-Oja, J. & Kinnula, V. L. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 10, 333\u2013342 (2008).","journal-title":"Antioxid Redox Signal"},{"key":"BFsrep03822_CR21","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1167\/iovs.12-10525","volume":"53","author":"G Groeger","year":"2012","unstructured":"Groeger, G., Doonan, F., Cotter, T. G. & Donovan, M. Reactive oxygen species regulate prosurvival ERK1\/2 signaling and bFGF expression in gliosis within the retina. Invest Ophthalmol Vis Sci 53, 6645\u20136654 (2012).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep03822_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2004-07-2958","volume":"105","author":"DJ Manalo","year":"2005","unstructured":"Manalo, D. J. et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105, 659\u2013669 (2005).","journal-title":"Blood"},{"key":"BFsrep03822_CR23","doi-asserted-by":"publisher","first-page":"16767","DOI":"10.1074\/jbc.M901790200","volume":"284","author":"DR Mole","year":"2009","unstructured":"Mole, D. R. et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284, 16767\u201316775 (2009).","journal-title":"J Biol Chem"},{"key":"BFsrep03822_CR24","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1186\/gb-2009-10-10-r113","volume":"10","author":"X Xia","year":"2009","unstructured":"Xia, X. & Kung, A. L. Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biol 10, R113 (2009).","journal-title":"Genome Biol"},{"key":"BFsrep03822_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/pros.10279","volume":"57","author":"AP Berger","year":"2003","unstructured":"Berger, A. P. et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57, 57\u201365 (2003).","journal-title":"Prostate"},{"key":"BFsrep03822_CR26","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1111\/j.1743-6109.2011.02416.x","volume":"8","author":"A Morelli","year":"2011","unstructured":"Morelli, A. et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 8, 2746\u20132760 (2011).","journal-title":"J Sex Med"},{"key":"BFsrep03822_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/08977199809002121","volume":"16","author":"M Royuela","year":"1998","unstructured":"Royuela, M. et al. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia and prostatic carcinoma. Growth Factors 16, 101\u2013110 (1998).","journal-title":"Growth Factors"},{"key":"BFsrep03822_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1006\/excr.1997.3525","volume":"232","author":"DM Peehl","year":"1997","unstructured":"Peehl, D. M. & Sellers, R. G. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 232, 208\u2013215 (1997).","journal-title":"Exp Cell Res"},{"key":"BFsrep03822_CR29","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1210\/jc.2002-020596","volume":"87","author":"H Rumpold","year":"2002","unstructured":"Rumpold, H. et al. Trans-differentiation of prostatic stromal cells leads to decreased glycoprotein hormone alpha production. J Clin Endocrinol Metab 87, 5297\u20135303 (2002).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep03822_CR30","first-page":"6021","volume":"62","author":"JA Tuxhorn","year":"2002","unstructured":"Tuxhorn, J. A., McAlhany, S. J., Yang, F., Dang, T. D. & Rowley, D. R. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62, 6021\u20136025 (2002).","journal-title":"Cancer Res"},{"key":"BFsrep03822_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1046\/j.1464-410X.1997.00479.x","volume":"80","author":"N Deshmukh","year":"1997","unstructured":"Deshmukh, N. et al. Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry. Br J Urol 80, 869\u2013874 (1997).","journal-title":"Br J Urol"},{"key":"BFsrep03822_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pros.2990160108","volume":"16","author":"H Mori","year":"1990","unstructured":"Mori, H. et al. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 16, 71\u201380 (1990).","journal-title":"Prostate"},{"key":"BFsrep03822_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/eje.0.1450303","volume":"145","author":"S Boget","year":"2001","unstructured":"Boget, S., Cereser, C., Parvaz, P., Leriche, A. & Revol, A. Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not. Eur J Endocrinol 145, 303\u2013310 (2001).","journal-title":"Eur J Endocrinol"},{"key":"BFsrep03822_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/(SICI)1097-0045(20000401)43:1<20::AID-PROS4>3.0.CO;2-6","volume":"43","author":"M Janssen","year":"2000","unstructured":"Janssen, M. et al. Cell lineage characteristics of human prostatic stromal cells cultured in vitro. Prostate 43, 20\u201330 (2000).","journal-title":"Prostate"},{"key":"BFsrep03822_CR35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0094-0143(21)00959-9","volume":"17","author":"H Lepor","year":"1990","unstructured":"Lepor, H. Role of long-acting selective \u03b1-blockers in the treatment of benign prostatic hyperplasia. Urol Clin N Amer 17, 651\u2013659 (1990).","journal-title":"Urol Clin N Amer"},{"key":"BFsrep03822_CR36","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/S0022-5347(01)63162-8","volume":"159","author":"N Kyprianou","year":"1998","unstructured":"Kyprianou, N. Litvak, J. P., Borkowski, A., Alexander, R. & Jacobs, S. C. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159, 1810\u20131815 (1998).","journal-title":"J Urol"},{"key":"BFsrep03822_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1254\/jphs.12067FP","volume":"119","author":"K Serizawa","year":"2012","unstructured":"Serizawa, K. et al. Paclitaxel-induced endothelial dysfunction in living rats is prevented by nicorandil via reduction of oxidative stress. J Pharmacol Sci 119, 349\u2013358 (2012).","journal-title":"J Pharmacol Sci"},{"key":"BFsrep03822_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejphar.2007.10.074","volume":"579","author":"M Tajima","year":"2008","unstructured":"Tajima, M., Ishizuka, N., Saitoh, K. & Sakagami, H. Nicorandil enhances the effect of endothelial nitric oxide under hypoxia-reoxygenation: role of the KATP channel. Eur J Pharmacol 579, 86\u201392 (2008).","journal-title":"Eur J Pharmacol"},{"key":"BFsrep03822_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1254\/jphs.09072FP","volume":"111","author":"H Sudo","year":"2009","unstructured":"Sudo, H. et al. Nicorandil improves glomerular injury in rats with mesangioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors. J Pharmacol Sci 111, 53\u201359 (2009).","journal-title":"J Pharmacol Sci"},{"key":"BFsrep03822_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/nau.22297","volume":"32","author":"M Saito","year":"2013","unstructured":"Saito, M. et al. Characterization of silodosin and naftopidil in the treatment of bladder dysfunction in the spontaneously hypertensive rat. Neurourol Urodyn 32, 393\u2013398 (2013).","journal-title":"Neurourol Urodyn"},{"key":"BFsrep03822_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/01.RES.14.2.164","volume":"14","author":"K Aukland","year":"1964","unstructured":"Aukland, K., Bower, B. F. & Berliner, R. W. Measurement of local blood flow with hydrogen gas. Circ Res 14, 164\u2013187 (1964).","journal-title":"Circ Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep03822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep03822","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep03822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T13:08:55Z","timestamp":1716469735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep03822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep03822"],"URL":"https:\/\/doi.org\/10.1038\/srep03822","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,22]]},"assertion":[{"value":"26 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3822"}}